M28 Capital has acquired an additional 2.85 million share in Adagio Therapeutics (ADGI) at an average of $4.28 per share, bringing its holding to 9.2 million, according to a report by 247WallStreet.
The report cites a 13D/A filing with the US Securities & Exchange Committee as revealing that the healthcare focused hedge fund now holds 8.5% of the company, having bought its first 5.6 million ADGI shares in May 2021 and a second tranche in April 2022.
M28 Capital, which also holds stakes in Wave Life Sciences, Rocket Pharmaceuticals Inc (RCKT), Stoke Therapeutics Inc (STOK) and BridgeBio Pharma (BBIO), is one of ADGI’s largest stock holders by market value as a result of the latest share acquisition.
